Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial.

The Lancet. Oncology·2026
Same author

2025 Update of the Taiwan Expert Consensus on Hormone Receptor-Positive Metastatic Breast Cancer Management.

Journal of breast cancer·2026
Same author

Integration of multi-omics for precision therapy in breast cancer.

Drug discovery today·2026
Same author

Rethinking Early-Stage Lymphedema: Severe Fat Accumulation Despite Early Lymphoscintigraphy Findings.

Plastic and reconstructive surgery·2026
Same author

The role of continuous in situ targeted antimicrobials in the successful treatment of extensively-drug resistant <i>Pseudomonas aeruginosa</i> left ventricular assist device driveline infection - A case report.

JHLT open·2026
Same author

The moderating and mediating effects of mindful compassion with body-mind-spirit therapy using a blended approach of face-to-face with online for breast cancer patients' depression during COVID-19: A randomized controlled trial.

Internet interventions·2026

Related Experiment Video

Updated: Jul 11, 2025

Endoscopic Bilateral Nipple-sparing Mastectomy via a Single Axillary Incision with Immediate Pre-pectoral Implant-based Breast Reconstruction
13:35

Endoscopic Bilateral Nipple-sparing Mastectomy via a Single Axillary Incision with Immediate Pre-pectoral Implant-based Breast Reconstruction

Published on: May 17, 2024

2.7K

Is Immediate Lymphatic Reconstruction on Breast Cancer Patients Oncologically Safe? A Preliminary Study.

Ying-Sheng Lin1, Chen-Hsiang Kuan2, Chiao Lo3,4

  • 1From the Division of Plastic Surgery, Department of Surgery, National Taiwan University Hospital Yunlin Branch, Yunlin County, Taiwan.

Plastic and Reconstructive Surgery. Global Open
|November 9, 2023
PubMed
Summary

Immediate lymphatic reconstruction (ILR) after axillary lymph node dissection (ALND) in breast cancer patients is oncologically safe. This technique does not increase the risk of distant cancer recurrence, offering a potential solution for lymphedema prevention.

More Related Videos

Ultrasonographic Evaluation of Breast Cancer-related Lymphedema
05:44

Ultrasonographic Evaluation of Breast Cancer-related Lymphedema

Published on: January 12, 2017

10.1K
Integrating Augmented Reality Tools in Breast Cancer Related Lymphedema Prognostication and Diagnosis
06:03

Integrating Augmented Reality Tools in Breast Cancer Related Lymphedema Prognostication and Diagnosis

Published on: February 6, 2020

6.7K

Related Experiment Videos

Last Updated: Jul 11, 2025

Endoscopic Bilateral Nipple-sparing Mastectomy via a Single Axillary Incision with Immediate Pre-pectoral Implant-based Breast Reconstruction
13:35

Endoscopic Bilateral Nipple-sparing Mastectomy via a Single Axillary Incision with Immediate Pre-pectoral Implant-based Breast Reconstruction

Published on: May 17, 2024

2.7K
Ultrasonographic Evaluation of Breast Cancer-related Lymphedema
05:44

Ultrasonographic Evaluation of Breast Cancer-related Lymphedema

Published on: January 12, 2017

10.1K
Integrating Augmented Reality Tools in Breast Cancer Related Lymphedema Prognostication and Diagnosis
06:03

Integrating Augmented Reality Tools in Breast Cancer Related Lymphedema Prognostication and Diagnosis

Published on: February 6, 2020

6.7K

Area of Science:

  • Oncology
  • Surgical Innovation
  • Lymphedema Management

Background:

  • Axillary lymph node dissection (ALND) for breast cancer can lead to arm lymphedema.
  • Immediate lymphatic reconstruction (ILR) using lymphovenous anastomosis is an emerging technique to mitigate this risk.
  • Concerns exist regarding the oncologic safety of ILR in node-positive axillas due to potential metastasis of residual cancer cells.

Purpose of the Study:

  • To evaluate the oncologic safety of immediate lymphatic reconstruction (ILR) in breast cancer patients undergoing axillary lymph node dissection (ALND).
  • To determine if ILR impacts the rate of distant cancer recurrence.

Main Methods:

  • A retrospective study comparing breast cancer patients who underwent ALND with and without ILR.
  • Inclusion criteria: ALND, follow-up ≥ 12 months, no recurrent cancer.
  • Outcome measured: Rate of distant recurrence after at least 1 year of follow-up.

Main Results:

  • Thirty-four patients in the ILR group and 32 in the non-ILR group met inclusion criteria.
  • No significant differences in baseline characteristics or adjuvant therapies between groups.
  • No statistically significant difference in distant recurrence rates between ILR and non-ILR groups (P=0.44) after ≥ 1 year follow-up.

Conclusions:

  • Immediate lymphatic reconstruction (ILR) with lymphovenous anastomosis is oncologically safe for breast cancer patients undergoing ALND.
  • ILR does not appear to increase the risk of distant cancer recurrence.
  • ILR is a viable option for lymphedema prevention in this patient population.